CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (34,232,093)	$ (11,006,794)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	831,258	426,440
Amortization of operating lease right-of-use assets	172,558	0
Stock compensation expense	2,069,343	3,006,203
Shares issued for services	334,400	0
Changes in fair value of contingent purchase consideration	0	(18,587,782)
Gain on write off of contingent consideration	(883,712)	0
Impairment of intangibles	937,953	99,519
Impairment of goodwill	4,411,784	188,069
Loss on settlement of debt	0	16,000
Amortization of debt discount	4,415,377	3,121,569
Non-cash interest expense from issuance on debt (derivative)	0	959,976
Change in fair value of derivative liabilities - convertible notes	(312,930)	988,267
Change in fair value of derivative liabilities - convertible warrants	255,197	(28,215)
Change in fair value of derivative liabilities - downside protection	5,061,164	(3,085,502)
Bad debt expense	10,981	3,252,439
Loss on disposal of fixed assets	189,364	0
Increase in notes payable due to default	527,929	0
Change in fair value of common stock payable	5,330	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(6,272)	(750,241)
Inventory	(113,177)	1,126,424
Accounts payable and accrued expenses	9,503,673	8,569,946
Interest payable to foundation	855,196	715,275
Accrued interest on notes receivable	0	1,387,763
Operating lease liabilities	(172,445)	0
Other current assets	5,480	49,248
Other assets, net	12,383	(22,797)
Net cash used in operating activities	(6,121,259)	(9,574,193)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,616)	(289,917)
Purchase of intangible assets	0	(26,487)
Disposal of property and equipment	0	292,681
Disposal of intangible assets	0	62,091
Cash received in acquisition of a business, net of cash paid	49,305	2,280,425
Net cash provided by investing activities	44,689	2,318,793
CASH FLOWS FROM FINANCING ACTIVITIES
Loan proceeds from related party	10,000	230,441
Payment of notes payable	(935,731)	(51,625)
Proceeds from note payable	6,626,418	6,329,910
Proceeds from issuance of common stock	109,770	0
Net cash provided by financing activities	5,810,457	6,508,726
Effects of currency translation on cash and cash equivalents	(16,920)	(1,206)
Net increase in cash and cash equivalents	(283,033)	(747,880)
Cash and cash equivalents, beginning of period	298,485	1,046,365
Cash and cash equivalents, end of period	15,452	298,485
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	25,000	0
Cash paid for taxes	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of derivative liabilities	4,593,765	0
Discount on Derivative liability upon issuance of debt	1,894,592	0
Set up of righ of use asset	210,698	0
Issuance of shares--common stock payable	936,395	0
Shares issued as debt issuance cost	151,230	0
Cancellation of shares	20,376	0
Issuance of debt for payment of prepaid expense	50,000	0
Settlement of subsidiary's debt with issuance of stock	32,212	0
Purchase of shares in subsidiary	6,571,811	0
Issuance of common stock for conversion of debt	5,348,847	8,257,918
Conversion of NuGenerex Diagnostics debt and issuance of call option	0	14,056,113
Exercise of call option	0	1,385,730
Issuance of warrants	0	5,592,244
Acquisition of Olaregen stock through issuance of notes payable	$ 0	$ 2,000,000